Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]NAV4694 PET for Beta-Amyloid Detection
NCT01886820Phase 3Unknown
- Sponsor
- Navidea Biopharmaceuticals, Inc.
- Start
- Jun 2013
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of flutafuranol in Alzheimer's disease (AD), sponsored by Navidea Biopharmaceuticals, Inc.. Status: unknown.
02
Drugs
flutafuranol
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01886820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01886820.